Active safety surveillance of COVID-19 mRNA vaccines in children aged 5-15 years in Australia
Wood, N.; Lopez, L. K.; Glover, C.; Leeb, A.; Cashman, P.; Deng, L.; Macartney, K.
Show abstract
AusVaxSafety (Australias active safety surveillance system) used SMS/email delivered surveys to actively solicit the short-term (within first 3 days after vaccination) adverse event profile of mRNA COVID-19 vaccines in children (aged 5-15 years) by age, dose, brand and pre-existing comorbidity. 392,268 survey responses for children aged 5-15 who received a COVID-19 vaccine between July 2021-May 2022 (211,994 following BNT162b2 10mcg in children aged 5-11 years, 173,329 following BNT162b2 30mcg and 6,945 following mRNA-1273 100mcg in adolescents aged 12-15 years) were analysed. Adverse event rates were higher following dose 2 and 3 compared to dose 1 after all vaccines and highest following dose 2 of mRNA-1273 in 12-15 years. Fever was low in the youngest children (5 years old, any dose; 1,090/26,181 (4%)). Medical review rates remained low (0.3% overall) and impact on daily activities was also low (7% overall). No self-reported cases of myocarditis or pericarditis were identified. Ongoing active safety surveillance of lower dose mRNA vaccines in children under 5 years old is required to better understand safety as the vaccines roll out into this population age-group.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A systematic review of spontaneously reported data from the UK, Europe, and the US and of the literature 95%
- COVID-19 vaccines and evidence-based medicine 95%
- COVID-19 vaccination effectiveness rates by week and sources of bias 94%
Similar papers in this journal
- Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection 95%
- Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study 94%
- Vaccinating Australia: How long will it take? 94%
Similar papers in this journal
- Safety and immunogenicity of the BBIBP-CorV vaccine in adolescents aged 12-17 years in Thai population, prospective cohort study 95%
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 95%
- Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021 94%
Similar papers in this journal
- Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273 95%
- Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study 94%
- Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against 1 JN.1 Subvariants in Adult Participants 93%
Similar papers in this journal
- General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study) 90%
- Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study. 87%
- Successful incorporation of a genetic risk prediction research platform into routine newborn screening 86%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.